Literature DB >> 32469265

Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an in silico insight into the comparative efficacy of repurposing antiviral drugs.

Muhammad Amin1, Ghazanfar Abbas1.   

Abstract

Recent outbreak of novel Coronavirus disease () pandemic around the world is associated with severe acute respiratory syndrome. The death toll associated with the pandemic is increasing day by day. SARS-CoV-2 is an enveloped virus and its N terminal domain (NTD) of Nucleocapsid protein (N protein) binds to the viral (+) sense RNA and results in virus ribonucleoprotien complex, essential for the virus replication. The N protein is composed of a serine-rich linker region sandwiched between NTD and C terminal (CTD). These terminals play a role in viral entry and its processing post entry. The NTD of SARS-CoV-2 N protein forms orthorhombic crystals and binds to the viral genome. Therefore, there is always a quest to target RNA binding domain of nucleocapsid phosphoprotein (NTD-N-protein which in turn may help in controlling diseases caused by SARS-CoV-2 in humans. The role of Chloroquine and Hydroxychloroquine as potential treatments for is still under debate globally because of some side effects associated with it. This study involves the In silico interactions of Chloroquine and Hydroxychloroquine with the NTD-N-protein of SARS-CoV-2. With the help of various computational methods, we have explored the potential role of both of these antiviral drugs for the treatment of patients by comparing the efficacy of both of the drugs to bind to NTD-N-protein. In our research Hydroxychloroquine exhibited potential inhibitory effects of NTD-N-protein with binding energy -7.28 kcal/mol than Chloroquine (-6.30 kcal/mol) at SARS-CoV-2 receptor recognition of susceptible cells. The outcomes of this research strongly appeal for in vivo trials of Hydroxychloroquine for the patients infected with . Furthermore, the recommended doses of Hydroxychloroquine may reduce the chances of catching to the healthcare workers and staff who are in contact with or delivering direct care to coronavirus patients as long as they have not been diagnosed with . We further hypothesize that the comparative NTD-N-protein -drug docking interactions may help to understand the comparative efficacy of other candidate repurposing drugs until discovery of a proper vaccine.Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  Coronaviruses; RNA binding domain of nucleocapsid phosphoprotein; SARS-CoV-2; chloroquine; docking studies; hydroxychloroquine

Year:  2020        PMID: 32469265     DOI: 10.1080/07391102.2020.1775703

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  8 in total

Review 1.  The pulmonary route as a way to drug repositioning in COVID-19 therapy.

Authors:  Michelle Alvares Sarcinelli; Thalita Martins da Silva; Andressa Daniele Artico Silva; Beatriz Ferreira de Carvalho Patricio; Flávia Costa Mendes de Paiva; Raissa Santos de Lima; Manuela Leal da Silva; Helvécio Vinícius Antunes Rocha
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-24       Impact factor: 5.062

Review 2.  The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.

Authors:  Subham Das; Anu Kunnath Ramachandran; Sumit Raosaheb Birangal; Saleem Akbar; Bahar Ahmed; Alex Joseph
Journal:  Med Drug Discov       Date:  2021-03-10

Review 3.  Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey.

Authors:  Estefanía Calvo-Alvarez; Maria Dolci; Federica Perego; Lucia Signorini; Silvia Parapini; Sarah D'Alessandro; Luca Denti; Nicoletta Basilico; Donatella Taramelli; Pasquale Ferrante; Serena Delbue
Journal:  Microorganisms       Date:  2022-06-24

Review 4.  Viewing SARS-CoV-2 Nucleocapsid Protein in Terms of Molecular Flexibility.

Authors:  Tatsuhito Matsuo
Journal:  Biology (Basel)       Date:  2021-05-21

5.  Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.

Authors:  Anca Pantea Stoian; Doina Catrinoiu; Manfredi Rizzo; Antonio Ceriello
Journal:  Diabetes Metab Res Rev       Date:  2020-07-20       Impact factor: 8.128

6.  Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents.

Authors:  Gizem Tatar; Ezgi Ozyurt; Kemal Turhan
Journal:  Biotechnol Prog       Date:  2020-12-30

7.  Tetracycline as an inhibitor to the SARS-CoV-2.

Authors:  Tom Y Zhao; Neelesh A Patankar
Journal:  J Cell Biochem       Date:  2021-02-22       Impact factor: 4.480

Review 8.  The Spike of SARS-CoV-2: Uniqueness and Applications.

Authors:  Ranjith Kumavath; Debmalya Barh; Bruno Silva Andrade; Madangchanok Imchen; Flavia Figueira Aburjaile; Athira Ch; Diego Lucas Neres Rodrigues; Sandeep Tiwari; Khalid J Alzahrani; Aristóteles Góes-Neto; Marianna E Weener; Preetam Ghosh; Vasco Azevedo
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.